Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer

Wen-Sy Tsai, Wei-Shan Hung, Tzu-Min Wang, Hsuan Liu, Chia-Yu Yang, Shao-Min Wu, Hsueh-Ling Hsu, Yu-Chiao Hsiao, Hui-Ju Tsai, Ching-Ping Tseng

Division of Colon and Rectal Surgery, Department of Surgery, Linko Ping Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
Graduate Institute of Clinical Medical Science, Chang Gung University, Taoyuan, Taiwan
Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan
Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

Abstract

Background: The immunochemical fecal occult blood test (iFOBT) for colorectal cancer (CRC) screening and the serum carcinoembryonic antigen (CEA) assay for disease detection of CRC is associated with a high false-positive rate and a low detection sensitivity, respectively. There is an unmet need to define additional modalities to complement these assays. Different subsets of circulating tumor cells (CTCs) are present in the peripheral blood of cancer patients. Whether or not CTCs testing supplements these clinical assays and is valuable for patients with CRC was investigated.

Methods: CTCs were enriched from pre-operative patients with CRC (n = 109) and the non-cancerous controls (n = 65). CTCs expressing either epithelial cell adhesion molecule (EpCAM) or podoplanin (PDPN, the marker associated with poor cancer prognosis) were defined by immunofluorescence staining and were analyzed alone or in combination with iFOBT or serum CEA.

Results: Patients with early or advanced stage of CRC can be clearly identified and differentiated from the non-cancerous controls (p < 0.001) by EpCAM+CTC or PDPN+CTC count. The sensitivity and specificity of EpCAM+-CTCs was 85.3% and 78.5%, respectively, when the cutoff value was 23 EpCAM+-CTCs/mL of blood; and the sensitivity and specificity of
Colorectal cancer (CRC) is among the most common cancers worldwide [1], and is the most common cancer in men and the second most common cancer in women in Taiwan [2,3]. CRC screening and disease monitoring are essential to reduce patient mortality. The immunochemical fecal occult blood test (iFOBT) is commonly used in population screening to identify individuals who have CRC without notice. People who have a positive iFOBT receive colonoscopy examination to confirm the occurrence of advanced stage adenomas and early cancer which if not treated may cause CRC mortality. However, the high false positive rate of iFOBT increases substantially the use and the cost associated with the use of colonoscopy resources [4]. A non-invasive and cost-effective method to supplement iFOBT to define individuals who have false positive iFOBT results should make iFOBT screening more practical.

Carcinoembryonic antigen (CEA), without satisfying accuracy, is now the only biomarker for CRC in the clinical setting. It is used not only for detection of CRC but also for monitoring disease status during treatment. However, elevated serum CEA was found in 72% of cases with unresectable or metastatic disease and in 3%, 25%, 45% and 65% of patients with Dukes’ A, B, C, and D, respectively [5,6]. Multiple imaging techniques including virtual colonoscopy, elastography, and dual-energy spectral computed tomography may supplement CEA results and offer surveillance of patients to avoid missed cases [7]. These procedures either are expensive or require exposure to radiation. Additional methods to supplement CEA assay for disease detection of patients with CRC are worthy to define.

Cancer cells are released into the blood stream even at the early stage of cancer [8]. Circulating tumor cells (CTCs) enumeration has been used to monitor treatment efficacy and the disease status of patients with CRC [9,10]. However, the detection rates of CTCs in different clinico-pathological conditions are various. The application of CTC enumeration in screening for early stage of cancer is also controversial [11–13]. Whether sufficient number of CTCs can be detected by a specific CTC assay mainly depends on the binding affinity of the capture antibody which in most studies targeting on the epithelial cell adhesion molecule (EpCAM) [14,15]. However, cancer cells usually undergo epithelial–mesenchymal transition (EMT) when they are released from the primary tumor site [16]. Phenotypic variation can occur in CTCs [17]. CTCs expressing EMT-related proteins such as N-cadherin, E-cadherin, vimentin, and the 38–40 kDa transmembrane molecule podoplanin (PDPN) have been identified in different cancer types [18–22]. Among these EMT-related proteins, PDPN expression was increased in almost all intestinal tumors (colon, rectum, and small intestine) compared with corresponding normal tissues [23,24]. PDPN is implicated in cancer progression [25–27] and cancer-associated thrombosis [28,29] by increasing cell spreading, collective and single cell migration and invasion [30], induction of RhoA activity, modulation of actin cytoskeleton [30] and inducing platelet aggregation by binding to the platelet C-type lectin-like receptor 2 (CLEC-2) [31,32]. On the other hand, PDPN regulates lymphatic vessel formation [33], cerebrovascular patterning and integrity [34], megakaryocyte proliferation, proplatelet formation [35], wound healing [36] and efficient T-cell priming [37], and maintains the integrity of high endothelial venules in lymph nodes [38] under physiological condition.

Negative selection by depleting CD45−leukocytes with anti-CD45 antibody provides a better strategy to enrich different subtypes of CTC [39,40]. PDPN-positive CTCs have been enriched by negative selection from patients with head and neck squamous cell carcinoma [18] and papillary thyroid carcinoma (PTC) [41]. Whether PDPN is expressed in the CTCs from patients with CRC has not yet been defined. Whether analysis of EpCAM−CTC and PDPN−CTC count supplements iFOBT to reduce the false positive results and when analyzed
together with CEA assay to provide better disease monitoring of patients are worthy to further investigation.

In this study, CTCs were enriched from patients at different stages of CRC by using a negative selection system [42]. The number of EpCAM$^+$-CTCs and PDPN$^+$-CTCs in CD45$^-$-depleted cell filtrates was determined. Combined analysis of CTC count with iFOBT or serum CEA was performed and correlated with the clinical status of patients with CRC. The significance of these findings was discussed.

**Materials and methods**

**Study subjects**

This study was approved by the Chang Gung Memorial Hospital Institutional Review Board (approval ID: 103–25298 and 1604190001). Written informed consent was given by all patients before inclusion in the study. A total of 109 patients with CRC and 65 non-cancerous controls were enrolled in the Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at Linko. Of the 109 CRC patients, 16 of them were at stage I, 36 at stage II, 47 at stage III, and 10 at stage IV, respectively. The Tumor-Node-Metastasis (TNM) classification of the tumor was based on the American Joint Committee on Cancer, seventh edition. All clinicopathologic parameters of patients were classified according to the chart records. Patients with other known cancers and multiple gastrointestinal tract diseases (such as polyps and ulcerative colitis) were excluded from the analysis.

Non-cancerous controls were divided into two groups based on colonoscopic exams and chart records. The individuals in group 1 (G1) had no previously known cancer and without any benign colorectal diseases at the time of the study. The individuals in group 2 (G2) had benign colorectal diseases such as hyperplastic, adenomatous, or severely dysplastic polyps. This prospective study was double-blinded in terms of both blood draw and CTC enumeration.

**Reagents**

The Alexa Fluor 488-conjugated donkey anti-mouse antibody, Alexa Fluor 555-conjugated donkey anti-rat antibody, and Hoechst 33342 were purchased from Invitrogen Inc. (Carlsbad, CA). The mouse anti-EpCAM antibody was purchased from Abcam Inc. (Cambridge, England). The anti-PDPN antibody was purchased from Angiobio (San Diego, CA).

**Depletion of CD45$^-$-leukocytes by PowerMag system**

CTCs were enriched by using a negative selection system PowerMag as previously described [42]. In brief, the red blood cells (RBC) in the fresh whole blood samples (4 ml) were lysed by RBC lysis buffer for 5 min at room temperature. After centrifugation at 400 g and 10$^\circ$C for 10 min and washing twice with culture medium, the nucleated cells were resuspended in culture medium (2 ml). CD45 depletion cocktail (StemCell Technologies, Vancouver, BC) was added to the nucleated cell suspension and incubated at room temperature for 15 min for depletion of CD45$^-$-leukocytes by capturing the cells in a PowerMag depletion column. The CD45$^-$-depleted cells were obtained by centrifugation of the cell filtrates at 400 g for 10 min. The cell pellets were subject to immunofluorescence staining for CTC enumeration.

**Immunofluorescence staining and CTC enumeration**

For immunofluorescence staining, CD45$^-$-depleted cell filtrates were incubated with the primary antibodies (anti-EpCAM or anti-PDPN) in the presence of the DNA staining dye Hoechst 33342 at room temperature for 1 h in the dark. After washing and centrifugation twice, the cell pellets were resuspended and incubated with the Alexa Fluor 488-conjugated (for EpCAM) or Alexa Fluor 555-conjugated (for PDPN) secondary antibodies in the dark for 30 min. After removing the unbound antibody, the cell aliquots were placed on a slide and the immunofluorescent images were captured by the fluorescence microscopy using automated slide scanning platform (Zeiss Axiovert 200M). Image analysis was performed by using the IN Cell Analyzer 1000 Cellular Imaging and Analysis System (GE Healthcare Life Sciences, Pittsburgh, PA). Hoechst-positive cells that are positive for EpCAM and

**Table 1 Basic information of patients enrolled in this study.**

| Variables               | No. of patient | median years | Interquartile range or percentage |
|-------------------------|----------------|--------------|---------------------------------|
| Age                     | 63             | 54–72        |
| Gender, male/female     | 67/42          |              |
| Tumor location          |                |              |
| Cecum                   | 7              | 6.4          |
| A-colon                 | 9              | 8.3          |
| T-colon                 | 13             | 11.9         |
| Splenic-flex            | 4              | 3.7          |
| D-colon                 | 12             | 11           |
| S-colon                 | 25             | 22.9         |
| Rectum                  | 39             | 35.8         |
| Tumor-node-metastasis staging | | | |
| Stage Ia                | 6              | 5.5          |
| Stage Ib                | 10             | 9.2          |
| Stage IIA               | 31             | 28.4         |
| Stage IIb               | 5              | 4.6          |
| Stage IIIa              | 29             | 26.6         |
| Stage IIIb              | 8              | 7.3          |
| Stage IIIC              | 10             | 9.2          |
| Stage IV                | 10             | 9.2          |
| Histological grade      |                |              |
| Well differentiation    | 9              | 8.3          |
| (Grade I)               |                |              |
| Moderate differentiation | 88             | 80.7         |
| (Grade II)              |                |              |
| Poor differentiation    | 12             | 11           |
| (Grade III-IV)          |                |              |
| T classification        |                |              |
| T0-2                    | 20             | 18.3         |
| T3-4                    | 89             | 81.7         |
| N classification        |                |              |
| N0-1                    | 102            | 93.6         |
| N2-3                    | 7              | 6.4          |
| M classification        |                |              |
| M0                      | 100            | 91.7         |
| M1                      | 9              | 8.3          |
PDNP were defined as EpCAM⁻-CTCs and PDNP⁺-CTCs, respectively.

**Serum CEA and iFOBT assays**

Serum CEA was determined by using an ADVIA Centaur® Analyzer (WI, USA) with the cutoff set at 5 ng/mL. The iFOBT was determined by using an ADVIA Centaur® Analyzer (WI, USA) with the cutoff set at 100 ng/mL.

**Statistical analysis**

CTC counts in non-cancerous control and in patients with CRC were compared using the Kruskal–Wallis test for all groups. The Dunn’s test was used as the post-hoc test between any two groups. The discrimination ability between any two groups was determined by using the ROC analysis. The correlations of the CTC count to iFOBT, and the CTC count to serum CEA assay were calculated using the Pearson Chi–Square test with cross-tabulation. Statistical analysis was performed using SPSS for Windows (version 18, SPSS, Chicago, IL). A p-value $< 0.05$ was considered statistically significant.

**Results**

**Basic characteristics of patients and non-cancerous controls**

Basic characteristics of patients enrolled in this study are shown in Table 1. The median age was 63 years with the interquartile range from 54 to 72. Rectum (35.8%) was the primary tumor site followed by S-colon (22.9%) and T-colon (11.9%) [Table 1]. The staging status of patients included stage I (14.7%), stage II (33.0%), stage III (43.1%), and stage IV (9.2%). The histological grade of 88 patients (80.7%) was classified as moderate differentiation (grade II). Eighty-nine patients (81.7%) were classified as T3-4 with the tumors invading through the muscularis propria into pericolecrtal tissues. The non-cancerous controls were gender-matched with the median age of 57 years and an interquartile range from 48 to 63 [Table 2].

**Differentiation of patients with CRC from non-cancerous controls by EpCAM⁺-CTC and PDNP⁺-CTC count**

PDNP is a marker for lymphatic vessels and is involved in cancer progression by mediating cancer cell-induced platelet aggregation and cancer-associated thrombosis [25–29]. The fragments per kilobase million files were downloaded from The Cancer Genome Atlas and combined for bioinformatic analysis to demonstrate the expression profile of PDNP in colorectal cancer. PDNP was increased in tumor tissues from patients with CRC when compared to the normal counterpart as determined by the analysis of variance model in the Partek Genomics Suite ($p < 0.001$, see Supplementary Fig. 1).

The negative selection system PowerMag [42] was used to enrich CTCs by depletion of CD45⁺ leukocytes. The EpCAM⁺ and PDNP⁺ cells in the CD45-depleted cell filtrates were defined by immunofluorescence staining [Fig. 1A]. The number of CTCs was determined and correlated with the clinical condition of patients [Table 2, Fig. 1B and C]. The median EpCAM⁺ and PDNP⁺ cell count for G1 control (healthy individuals) was 10 (interquartile range 4–21) and 5 (interquartile range 2–8) cells/ml of blood, respectively. The median EpCAM⁺ and PDNP⁺ cell count for the G2 control (individuals with benign polyps) was 13 (interquartile range 7–25) and 5 (interquartile range 3–8) cells/ml of blood, respectively. EpCAM⁺ and PDNP⁺ cell count was not significantly different between G1 and G2, implying that non-cancerous benign disorders of colorectal tissues do not increase cell release from colorectal tissues into the circulatory system.

The median EpCAM⁺-CTC and PDNP⁺-CTC count for patients with CRC was 109 (interquartile range 31–237) and 24 (interquartile range 8–56) cells/ml, respectively [Table 2]. The number of both CTC subtypes was significantly increased when compared to the individuals who were considered as healthy without cancer history and who had benign colorectal disease [$p < 0.0001$, Table 2, Fig. 1B and C]. The EpCAM⁺-CTC count distinguished patients with CRC from non-cancerous controls (G1 + G2). The area under the curve (AUC) in a receiver operating characteristic (ROC) analysis was 0.8602 [$p < 0.0001$, Fig. 2A]. The sensitivity and specificity of the assay was 85.3% and 78.5%, respectively, when the cutoff was set at 23 EpCAM⁺ cells/ml [Fig. 2A]. PDNP⁺-CTCs distinguished patients with CRC from non-cancerous controls (G1 + G2) with the AUC equivalent to 0.8126 [$p < 0.0001$, Fig. 2B]. The sensitivity and specificity of the assay was 78.0% and 75.4%, respectively.

### Table 2 Basic characteristics and CTC count of the study subjects.

| Characteristics | Gender (M/F) | Age (year)ᵃ | EpCAM⁺ cells/mlᵇ | PDNP⁺ cells/mlᵇ |
|-----------------|--------------|-------------|------------------|-----------------|
| Controls (n = 65) | 38/27 | 57 (48–63) | 11 (5–23) | 5 (3–8) |
| Healthy individuals (G1, n = 25) | 12/13 | 55 (47–61) | 10 (4–21) | 5 (2–8) |
| Benign polyps (G2, n = 40) | 26/14 | 58 (48–64) | 13 (7–25) | 5 (3–8) |
| Patients (n = 109) | 67/42 | 63 (54–72) | 109 (31–237) | 24 (8–56) |
| Stage I (n = 16) | 14/2 | 70 (54–76) | 194 (24–420) | 32 (8–72) |
| Stage II (n = 36) | 22/14 | 65 (52–73) | 159 (42–283) | 32 (8–69) |
| Stage III (n = 47) | 25/22 | 62 (55–68) | 63 (25–186) | 15 (6–43) |
| Stage IV (n = 10) | 6/4 | 64 (49–66) | 118 (48–251) | 33 (14–46) |
| p-valueᶜ | 0.165 | 0.003 | <0.0001 | <0.0001 |

ᵃ Data represent the median and interquartile range for the indicated parameters.
ᵇ Statistical analysis was performed for comparing controls (G1 and G2) with patients.
ᶜ Statistical analysis was performed for comparing controls (G1 and G2) with patients.
Fig. 1 Fluorescence images of EpCAM\(^+\) and PDPN\(^+\) cells and the scatter dot plots for the number of EpCAM\(^+\) and PDPN\(^+\) cells in the indicated groups of individuals. (A) Immunofluorescence staining was performed to define EpCAM\(^+\) and PDPN\(^+\) cells using the anti-EpCAM and anti-PDPN antibody, respectively. The cells that were positive to Hoechst 33342 staining indicate intact nucleated cells. Bar = 10 \(\mu\)m. (B–C) The scatter dot plots for EpCAM\(^+\) (panel B) and PDPN\(^+\) (panel C) cell count obtained from individuals without colorectal diseases (healthy individuals, \(n = 25\)), with benign colorectal diseases (benign polyps, \(n = 40\)), and with CRC (patients, \(n = 109\)). Statistical analysis was performed by using the Kruskal–Wallis test. The Dunn’s test was used for post-hoc analysis. The median for each group are indicated by horizontal line. ***\(p < 0.001\).
respectively, when the cutoff was set at 7 cells/ml for PDPN$^+$-CTCs [Fig. 2B].

EpCAM$^+$-CTC count was not significantly different among patients at different clinical stages [see Supplementary Table S1]. The median EpCAM$^+$-CTC count was 194 (interquartile range 24–420), 159 (interquartile range 42–283), 63 (interquartile range 25–186) and 118 (interquartile range 48–251) cells/ml for patients at stage I, II, III and IV, respectively [Table 2 and Fig. 3A]. The EpCAM$^+$-CTC count was significantly different between G1 and all stages of patients ($p < 0.0001$), and between G2 and all stages of patients ($p < 0.0001$). PDPN$^+$-CTC count was not significantly different among patients at different clinical stages. The median PDPN$^+$-CTC count was 32 (interquartile range 8–72), 32 (interquartile range 8–69), 15 (interquartile range 6–43) and 33 (interquartile range 14–46) cells/ml for patients at stage I, II, III and IV, respectively [Table 2 and Fig. 3B]. The PDPN$^+$-CTC count was significantly different between G1 and all stages of patients (stage I, $p < 0.001$; stages II, III, and IV, $p < 0.0001$), and between G2 and all stages of patients (stage I, $p < 0.001$; stages II, III, and IV, $p < 0.0001$). These results reveal that either EpCAM$^+$-CTC or PDPN$^+$-CTC counts can differentiate patients with CRC from the individuals with benign polyps or without cancer history.

**Combined analysis of CTC count and iFOBT reduced the false positive results of iFOBT**

The iFOBT is a cost-effective and non-invasive screening method for CRC with a high false positive rate. This prompted an investigation of whether or not combined analysis of CTC and iFOBT reduced the false positive rate of iFOBT. In the non-cancerous control group (G1 + G2), 24 of the 36 individuals who were iFOBT-positive (66.6%) had an EpCAM$^+$-CTC count below the cutoff set at 23 cells/ml. Twenty-four of the 28 patients who were iFOBT-positive (85.7%) was confirmed by high EpCAM$^+$-CTC count [Table 3]. Similarly, 21 of the 36 non-
cancer controls who were iFOBT-positive (58.3%) had an PDPN⁺-CTC count less than the cutoff set at 7 cells/ml. Twenty-two of the 28 patients who were iFOBT-positive (78.6%) was confirmed by high PDPN⁺-CTC count [Table 3]. These data demonstrate that analysis of EpCAM⁺-CTC and PDPN⁺-CTC count could reduce the false positive results of iFOBT.

**Combined analysis of CTC count and serum CEA facilitates disease detection of patients with CRC**

CEA is the clinical biomarker to indicate the progression or recurrence of CRC. However, serum CEA is increased in only 3%–65% of the patients [43,44]. When serum CEA was measured preoperatively, only 33 of the 109 patients (30.3%) had an increase in CEA (≥5 ng/ml) [Table 4]. Of the 76 patients with CEA <5 ng/ml, 64 (84.2%) and 61 (80.3%) patients had EpCAM⁺-CTCs ≥23 cells/ml and PDPN⁺-CTCs ≥7 cells/ml, respectively. Combined analysis of serum CEA with EpCAM⁺-CTC and PDPN⁺-CTC count increased the positive detection rate of CRC to 89.0% (97 patients with EpCAM⁺-CTCs ≥23 and/or CEA ≥5) and 86.2% (94 patients with PDPN⁺-CTCs ≥7 cells/ml and/or CEA ≥5), respectively [Table 4]. Using EpCAM⁺-CTCs ≥23 as the cutoff, the positive detection rate among patients with CEA <5 were 92.8% (n = 13), 83.3% (n = 20), 78.8% (n = 26), 100% (n = 5) in the groups of stage I, II, III, and IV, respectively [Table 4]. When using PDPN⁺-CTCs ≥7 cells/ml as the cutoff, the positive detection rate among patients with CEA < 5 were 78.6% (n = 11), 79.2% (n = 20), 75.8% (n = 25), 100% (n = 5) in the groups of stage I, II, III, and IV, respectively [Table 4]. Regardless of the clinical stage of patients, 84.2% and 80.3% of CRC patients with CEA < 5 ng/ml had the EpCAM⁺-CTC and PDPN⁺-CTC count above the cutoff, respectively. Combined analysis of CTC count and CEA is superior to CEA assay alone in disease detection of patients with CRC.

**Table 3 Combined analysis of CTC count and iFOBT reduced false positive iFOBT results.**

| iFOBT⁺ | EpCAM⁺ cells/ml | PDPN⁺ cells/ml |
|--------|-----------------|----------------|
| <23    | ≥23             | <7             |
| No. of case (%)² | No. of case (%)³ | No. of case (%)³ |
| Non-cancerous controls | 24 (66.6%) | 12 (33.4%) | 21 (58.3%) | 15 (41.7%) |
| CRC patients (n = 28) | 4 (14.3%) | 24 (85.7%) | 6 (21.4%) | 22 (78.6%) |
| Total | 28 (43.8%) | 36 (52.2%) | 27 (42.2%) | 37 (57.8%) |
| p value⁴ | <0.0001        | <0.0001        |       |       |

² Data represent the number of cases and the percentage of individuals at the indicated category.
³ Statistical analysis was performed by Person Chi-Square test.

**Table 4 Combined analysis of CTC count and serum CEA facilitates disease monitoring of patients with CRC.**

| CEA (ng/ml) | EpCAM⁺-CTCs (cells/ml) | PDPN⁺-CTCs (cells/ml) |
|-------------|------------------------|------------------------|
| <5 (n = 76) | 12 (15.8%) | 64 (84.2%) | 15 (19.7%) | 61 (80.3%) |
| Stage I (n = 14) | 1 (7.2%) | 13 (92.8%) | 3 (21.4%) | 11 (78.6%) |
| Stage II (n = 24) | 4 (16.7%) | 20 (83.3%) | 4 (20.8%) | 20 (79.2%) |
| Stage III (n = 33) | 7 (21.2%) | 26 (78.8%) | 8 (24.2%) | 25 (75.8%) |
| Stage IV (n = 5) | 0 (0.0%) | 5 (100%) | 0 (0.0%) | 5 (100%) |
| ≥5 (n = 33) | 4 (12.1%) | 29 (87.9%) | 6 (18.2%) | 27 (81.8%) |
| Stage I (n = 2) | 0 (0.0%) | 2 (100%) | 0 (0.0%) | 2 (100%) |
| Stage II (n = 12) | 1 (8.3%) | 11 (91.7%) | 1 (8.3%) | 11 (91.7%) |
| Stage III (n = 14) | 3 (21.4%) | 11 (78.6%) | 4 (28.6%) | 10 (71.4%) |
| Stage IV (n = 5) | 0 (0%) | 5 (100%) | 1 (20.0%) | 4 (80.0%) |
| Total (n = 109) | 16 (14.7%) | 93 (85.3%) | 21 (19.3%) | 88 (80.7%) |

* Data represent the number of cases and the percentage of patients with the indicated CEA results or clinical stages.
Discussion

Peripheral blood is an important biological resource for screening and disease detection of patients with cancer. In this study, CTCs expressing EpCAM or PDPN were defined to present in the early and late stages of CRC patients. By CTC testing alone, both EpCAM$^+$-CTCs and PDPN$^+$-CTC count clearly distinguishes patients with CRC from non-cancerous control. CTC enumeration when combined analysis with iFOBT results significantly reduced the false positive rate of iFOBT, while when combined analysis with serum CEA improved the detection rate of patients with CRC. This study thereby paves the way for implementation of CTC testing in screening and disease detection of patients with CRC.

CTCs are composed of heterogeneous populations with distinct cellular properties [17,45,46]. Different subsets of CTCs have distinct impacts on disease progression of patients. For example, the number of CTCs expressing CD133$^+$ correlates with liver metastasis in patients with CRC [47]. We compared and analyzed CTC subsets with EpCAM or PDPN expression. PDPN is frequently up-regulated in squamous cell carcinoma, thyroid cancer, ovarian cancer, germinal neoplasia, and central nervous system tumors with increased motility and metastasis [48–53]. PDPN causes cancer-associated thrombosis and cancer progression in human and animal models [28,49]. PDPN$^+$ cells are present in the peripheral blood of patients with CRC. Not all PDPN$^+$ cells were EpCAM$^+$ (data not shown). This is consistent with the finding that PDPN is present in both cancer cells and cancer-associated fibroblasts in the stroma surrounding CRC tumor tissue [54–58]. Pericryptal stromal cells expressing PDPN is associated with epithelial tumor development in the colorectum [59]. The biology and the pathological significances related to PDPN expression in the peripheral blood of patients with CRC are worthy to further investigation.

CTCs are detectable not only when cancer cells metastasize [60,61], but also at the early stage of cancer when metastases are not evident [62–64]. CTCs have been found in 69% of patients with the T1/T2 stage of breast cancer [65]. Both early- and late-stage lung cancer CTCs have been reported when using stringent morphologic inclusion criteria for characterizing high definition CTCs (HD-CTCs) [66]. CTCs were detected in the early stage of CRC patients and had prognostic value in non-metastatic CRC [67,68]. The number of CTCs is correlated with tumor mass, with a higher number of CTCs in the late stage of cancer and a lesser number of CTCs in the early stage of cancer [69]. In this study, the median CTC count was not different among CRC patients with disease status of stage I to stage IV. The finding is consistent with a large cohort study of CRC [68]. No difference for the HD-CTCs counts among stages I, II, and III of patients with non-small cell lung cancer has also been reported [66]. Whether the methods to enrich CTCs, the different time points of blood collection, and the differences in clinico-pathological characteristics of the patients account for the different findings among these studies requires further investigation. We noted that the EpCAM$^+$-CTCs and PDPN$^+$-CTCs counts at stage III is lower when compared to the other stages. This is likely related to the occurrence of EMT during cancer progression [16]. The slight increase in the CTC count at stage IV when compared to stage III may reflect the balance of increased release of CTCs and the occurrence of EMT. The use of additional markers which are related to cancer progression or EMT may further improve late stage cancer detection with CTC counting.

CRC screening is crucial in effective management of cancer patients. Most current methods do not provide sufficient sensitivity. The iFOBT is a relatively simple method for CRC screening. However, it usually associates with high false positive rate [70]. Although colonoscopy is the gold standard in the initial diagnosis of CRC following iFOBT, not all individuals are comfortable with this invasive procedure. In this study, analysis of CTC count and iFOBT data obtained from healthy controls and patients prior to surgical operation revealed that CTC testing is able to reduce the false positive rate of iFOBT. Because CTC testing requires only one blood draw from the individual, implementation of CTCs testing into the surveillance program of CRC for combined analysis with iFOBT most likely leads to better and practical screening program.

Detection of disease status is important for management of patients with CRC. Serum biomarkers such as CEA are commonly used in the clinical setting. With about 30% patients have no elevated serum CEA, there is an unmet need for additional modalities to follow up treatment response and the occurrence of recurrence. CTC enumeration compromises serum thyroglobulin (Tg) testing when the anti-Tg antibody was present in patients with PTC [71]. Combined analysis of CTC count and serum Tg testing is superior to serum Tg testing alone in establishing the disease status of patients [71]. Supplement of standard medical tests by sequential CTC enumeration during therapy can benefit the management of patients who have locally advanced or metastatic HCC but with low AFP expression [72]. This concept was applied in the current study to investigate whether CTC testing can supplement serum CEA assay to increase disease detection rate in patients with CRC. We demonstrated in this study that 85% of CRC patients had elevated CTC count and/or serum CEA, while only 30% of patients in our cohort including 12.5% of patients who have locally advanced or metastatic HCC but with low AFP expression [72]. This concept was applied in the current study to investigate whether CTC testing can supplement serum CEA assay to increase disease detection rate in patients with CRC. We demonstrated in this study that 85% of CRC patients had elevated CTC count and/or serum CEA, while only 30% of patients in our cohort including 12.5% of patients who have locally advanced or metastatic HCC but with low AFP expression [72]. This concept was applied in the current study to investigate whether CTC testing can supplement serum CEA assay to increase disease detection rate in patients with CRC. We demonstrated in this study that 85% of CRC patients had elevated CTC count and/or serum CEA, while only 30% of patients in our cohort including 12.5% of patients who have locally advanced or metastatic HCC but with low AFP expression [72].

Conclusions

CTCs are heterogeneous and distinct subsets of CTCs express PDPN or EpCAM. These cells were found in patients with CRC. CTC testing is an assay that could be more frequently performed when compared to the standard methods for screening and disease detection of patients with CRC. The findings of the current study imply that CTC testing can supplement iFOBT or serum CEA measurement and may benefit clinical management of patients with CRC, in particular for CRC screening and for disease detection of patients without elevated serum CEA.
Supplementary data to this article can be found online at Appendix A. Supplementary data

This work was funded by the Chang Gung Medical Foundation [grant numbers CMRPD1G0081 to W.-S.T. and C.-P.T.]

We appreciate Professor Arnold Stern (New York University School of Medicine) for the editorial help in the preparation of this manuscript.

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

We appreciate Professor Arnold Stern (New York University School of Medicine) for the editorial help in the preparation of this manuscript.

Supplementary data to this article can be found online at https://doi.org/10.1016/j bj.2020.09.006.

REFERENCES

[1] Forman D, Bray F, Brewster DH, Combe MC, Kohler B, Piñeros M, et al. Cancer incidence in five continents, vol. X. Lyon, France: IARC Scientific Publications; 2014.
[2] Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS. Taiwan cancer registry task force. Cancer trends in Taiwan. Jpn J Clin Oncol 2010;40:897–904.
[3] Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos Med Assoc 2016;115:1076–88.
[4] Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomark Prev 2014;23:1712–28.
[5] Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–79.
[6] Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev 2015;10:CD011134.
[7] García-Figueiras R, Baleato-González S, Padhani AR, Luna-Alcalá A, Marhuenda A, Vilanova JC, et al. Advanced imaging techniques in evaluation of colorectal cancer. Radiographics 2018;38:740–65.
[8] Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet 2019;51:1113–22.
[9] Hardingham JE, Grover F, Winter M, Hewett PJ, Price TJ, Thierry B. Detection and clinical significance of circulating tumor cells in colorectal cancer—20 years of progress. Mol Med 2015;21:S25–31.
[10] Lianidou ES, Markou A, Strati A. The role of CTCs as tumor biomarkers. Adv Exp Med Biol 2015;867:341–67.
[11] Castro J, Sanchez L, Nuñez MT, Lu M, Castro T, Sharir HR, et al. Screening circulating tumor cells as a noninvasive cancer test in 3388 individuals from high-risk groups (ICELLATE2). Dis Markers 2018;2018:4653109.
[12] Ried K, Eng P, Sali A. Screening for circulating tumour cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study. Asian Pac J Cancer Prev APJCP 2017;18:2275–85.
[13] Maly V, Maly O, Kolostova K, Bobek V. Circulating tumor cells in diagnosis and treatment of lung cancer. In Vivo 2019;33:1027–37.
[14] Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 2010;11:1–13.
[15] Souza E Silva V, Chinen LT, Abdallah EA, Damascena A, Paludo J, Chojniak R, et al. Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. OncoTargets Ther 2016;9:7503–13.
[16] Gurzu S, Silveanu C, Fetyko A, Buturca V, Kovacs Z, Jung I. Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer. World J Gastroenterol 2016;22:6764–75.
[17] Brouwer A, De Laere B, Peeters D, Peeters M, Salgado R, Dirix L. Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget 2016;7:48625–43.
[18] Hsieh JC, Lin HC, Huang CY, Hsu HL, Wu TM, Lee CL, et al. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck 2015;37:1448–55.
[19] Zhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, et al. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Canc Cell Int 2017;17:6.
[20] Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vieilh P, et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 2016;16:168.
[21] Balasubramanian P, Lang JC, Jatana KR, Miller B, Ozer E, Old M, et al. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PloS One 2012;7:e42048.
[22] Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Canc Res 2011;9:997–1007.
[23] Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003;278:51599–605.

[24] Hu L, Zhang P, Sun W, Zhou L, Chu Q, Chen Y. PDPN is a prognostic biomarker and correlated with immune

Conflicts of interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Acknowledgments

We appreciate Professor Arnold Stern (New York University School of Medicine) for the editorial help in the preparation of this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j bj.2020.09.006.
infiltrating in gastric cancer. Medicine (Baltim) 2020;99:e19957.

[25] Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005;26:195–200.

[26] Fujita N, Takagi S. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J Biochem 2012;152:407–13.

[27] Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PloS One 2013;8:e73609.

[28] Lee HY, Yu NY, Lee SH, Tsai HJ, Wu CC, Cheng JC, et al. Podoplanin promotes cancer-associated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J 2020;43:146–62.

[29] Mir Seyed Nazari P, Riedl J, Pabinger I, Ay C. The role of podoplanin in cancer-associated thrombosis. Thromb Res 2018;164:S34–9.

[30] Li YY, Zhou CX, Gao Y. Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and Rho GTPases. Am J Cancer Res 2015;5:514–29.

[31] Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T. The platelet aggregation-inducing factor agrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007;170:1337–47.

[32] Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y. Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007;282:25993–6001.

[33] Osada M, Inoue O, Ding G, Shirai T, Ichise H, Hirayama K, Osada M, Inoue O, Ding G, Shirai T, Sasaki T, Kumar V, Dasoveanu DC, Chyou S, Tzeng TC, Rozo C, Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem 2012;287:22241–52.

[34] Lowe KL, Finney BA, Deppermann C, Hagerling R, Gazit SL, Frampton J. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood 2015;125:3769–77.

[35] Tamura S, Suzuki-Inoue K, Tsukiji N, Shirai T, Sasaki T, Osada M. Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2. Blood 2016;127:1701–10.

[36] Honma M, Minami-Hori M, Takahashi H, Iizuka H. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGF-beta and STAT-3 activating cytokines, IFN-gamma, IL-6, and IL-22. J Dermatol Sci 2012;65:134–40.

[37] Kumar V, Dasoveanu DC, Chyou S, Tseng TC, Roco C, Liang Y. A dendritic-cell-stromal axis maintains immune responses in lymph nodes. Immunity 2015;42:777–89.

[38] Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 2013;502:105–9.

[39] Lustberg MB, Zborowski M, et al. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 2013;64:169–82.

[40] Wu Y, Deighan CJ, Miller BL, Balsevich FB, Lustberg MB, Zborowski M, et al. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 2013;64:169–82.

[41] Lin JD, Liu M, Hsu HL, Leong KK, Chen YT, Wang YR, et al. Circulating epithelial cell characterization and correlation with remission and survival in patients with thyroid cancer. Thyroid 2018;28:1479–89.

[42] Lin HC, Hsu HC, Hsieh CH, Wang HM, Huang CY, Wu MH, et al. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta 2013;419:77–84.

[43] Bel Hadj Hmida Y, Tahri N, Sellami A, Yangui N, Jlidi R, Beyrouti M, et al. Sensitivity, specificity and prognostic value of CEA in colorectal cancer: results of a Tunisian series and literature review. Tunis Med 2001;79:434–40. French.

[44] Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Bugh S, et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PloS One 2017;12:e0171810.

[45] Wu Y, Park KJ, Deighan C, Amaya P, Miller B, Pan Q, et al. Multiparameter evaluation of the heterogeneity of circulating tumor cells using integrated RNA in situ hybridization and immunocytochemical analysis. Front Oncol 2016;6:234.

[46] Gorges TM, Kuske A, Röck K, Mauermaier O, Müller V, Peise S, et al. Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin Chem 2016;62:194–195.

[47] Fang C, Fan C, Wang C, Huang Q, Meng W, Yu Y, et al. CD133+/CD54−/CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer. Oncotarget 2016;7:77389–403.

[48] Astaria JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012;3:283.

[49] Riedl J, Preusser M, Nazari FM, Posch F, Panzer S, Marosi C, Fuchs H, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017;129:1831–9.

[50] Miyashita T, Higuchi Y, Kojima M, Ochiiai A, Ishii G. Single cell time-lapse analysis reveals that podoplanin enhances cell survival and colony formation capacity of squamous cell carcinoma cells. Sci Rep 2017;7:39971.

[51] Cobec IM, Sas I, Pirtea L, Cimpean AM, Moataf AE, Ceausu RA, et al. Podoplanin as key player of tumor progression and lymph vessel proliferation in ovarian cancer. Anticancer Res 2016;36:5265–72.

[52] Rudzinska M, Gaweł D, Sikorska J, Karpińska KM, Kiedrowski M, Stepień T, et al. The role of podoplanin in the biology of differentiated thyroid cancers. PloS One 2014;9:e96541.

[53] Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, et al. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget 2015;6:42733–48.

[54] Yamanashi T, Nakashiyama Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 2009;77:53–62.

[55] Choi SY, Sung R, Lee SJ, Lee TG, Kim N, Yoon SM, et al. Podoplanin, a-smooth muscle actin or S100A4 expressing cancer-associated fibroblasts are associated with different clinical outcome in patients with colorectal cancer. J Korean Med Sci 2016;31:1340–9.

[56] Kim SJ, Cheong JS, Kim EH, Yun J, Park JH, et al. The role of CD133+ cell-free DNA in the prediction of postoperative recurrence after curative resection of colorectal cancer. Jpn J Clin Oncol 2016;46:421–8.

[57] Choi SY, Sung R, Lee SJ, Lee TG, Kim N, Yoon SM, et al. Podoplanin, a-smooth muscle actin or S100A4 expressing cancer-associated fibroblasts are associated with different clinical outcome in patients with colorectal cancer. J Korean Med Sci 2016;31:1340–9.
[57] Inoue H, Tsuchiya H, Miyazaki Y, Kikuchi K, Ide F, Sakashita H, et al. Podoplanin expressing cancer-associated fibroblasts in oral cancer. Tumour Biol 2014;35:11345–52.

[58] Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Canc 2013;12:168.

[59] Nakayama H, Enzan H, Yasui W. Expression of podoplanin/D2-40 in pericytchal stromal cells in superficial colorectal epithelial neoplasia. Med Mol Morphol 2013;46:20–3.

[60] Fidler JJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453–8.

[61] Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649–69.

[62] Deryugina EI, Kiosses WB. Intratumoral cancer cell intravasation can occur independent of invasion into the adjacent stroma. Cell Rep 2017;19:601–16.

[63] Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, et al. Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). Eur J Cardiothorac Surg 2013;43:911–4.

[64] Coumans FA, Siesling S, Terstappen LW. Detection of cancer before distant metastasis. BMC Cancer 2013;13:283.

[65] Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, et al. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 2014;147:325–33.

[66] Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 2012;9:016005.

[67] Bork U, Rahbari NN, Schölich S, Reissfelder C, Kahler C, Büchler MW, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer 2015;112:1306–13.

[68] Zhao R, Cai Z, Li S, Cheng Y, Gao H, Liu F, et al. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget 2017;8:9293–302.

[69] Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep 2016;6:24517.

[70] Sokoro A, Singh H. Fecal occult blood test for evaluation of symptoms or for diagnostic testing. Am J Gastroenterol 2020;115:679–80.

[71] Lin HC, Liou MJ, Hsu HL, Hsieh JC, Chen YA, Tseng CP, et al. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma. Oncotarget 2016;7:17242–53.

[72] Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, et al. Sequential circulating tumor cell counts in patients with locally advanced or metastatic hepatocellular carcinoma: monitoring the treatment response. J Clin Med 2020;9:188.